Interstitial Lung Disease Care in Jaipur

What Interstitial Lung Disease Is and How It Happens

Interstitial lung disease (ILD) is a group of conditions that cause scarring, called fibrosis, in the tissue between the air sacs of the lungs. This tissue is called the interstitium. When it becomes thick and stiff, the lungs cannot expand fully, and oxygen finds it harder to pass into the blood. The scarring is usually long-term and tends to get worse over time.

In idiopathic pulmonary fibrosis (IPF), the most common form of ILD, the cause is not known. Earlier thinking suggested general inflammation led to scarring. Current evidence points to repeated injury to the cells lining the air sacs from things like smoke or environmental dust. This injury triggers repair cells to make excess scar tissue.

The result is a pattern called usual interstitial pneumonia (UIP), seen on scans as honeycombing and traction bronchiectasis in the lower, outer parts of the lungs.

Other ILDs include:

• Hypersensitivity pneumonitis
• Connective tissue disease related ILD
• Occupational lung diseases

Some of these behave like IPF and are called progressive pulmonary fibrosis (PPF). PPF is defined by at least two of three worsening signs over a year: worse symptoms, a drop in lung function (FVC decline of 5% or more, or DLCO decline of 10% or more), or new scarring on HRCT.

The prevalence of ILD varies widely, from 6.3 to 71 per 100,000 people globally. Among people aged 55 to 64, the incidence of IPF is about 19.3 cases per 100,000 person-years.

Symptoms of Interstitial Lung Disease and Warning Signs That Need Urgent Care

The most common symptoms of IPF are breathlessness and a dry cough. Breathlessness usually starts with effort, such as walking up a slope or stairs. The cough is often described as dry and hacking, sometimes beginning with a tickle in the throat.

A doctor listening to the chest with a stethoscope often hears fine crackling sounds at the lung bases when you breathe in. These inspiratory crackles are found in more than 90% of patients. Finger clubbing, where the fingertips become rounded and swollen, occurs in 25% to 50% of patients.

Warning signs that need medical attention the same day include a sudden increase in breathlessness, new or worsening cough with fever, coughing up blood, or confusion and drowsiness. These may signal an acute exacerbation, a rapid worsening of the disease that can be life-threatening.

Patients with IPF are also at higher risk for lung infections, pulmonary hypertension, and heart disease, which can cause sudden symptoms.

Causes and Who Is at Higher Risk for Interstitial Lung Disease

The exact cause of IPF is unknown. Risk increases with age, and the disease most often occurs in people older than 50. Men are affected more often than women. A history of smoking is a strong risk factor. Exposure to occupational or environmental dusts, fumes, or antigens also raises risk.

For women younger than 60, doctors keep a high index of suspicion for connective tissue disease as an underlying cause.

IPF is rarely inherited, but a family history can increase risk.

Other medical conditions often seen with IPF include:

• Coronary artery disease
• Lung cancer
• Obstructive sleep apnea
• Emphysema
• Pulmonary hypertension
• Gastro-oesophageal reflux disease
• Hiatal hernia
• Diabetes

These comorbidities add to the complexity of care and can increase the cost of treatment.

How Interstitial Lung Disease Is Diagnosed: Examination and Tests

Diagnosing ILD is often an exercise in ruling out other conditions. No single test confirms the diagnosis; the whole clinical picture is considered. Misdiagnosis is common. In one study, IPF was most often mistaken for asthma (13.5%), pneumonia (13.0%), or bronchitis (12.3%).

Delays in diagnosis of one to three years have been reported, and longer delays are linked to a higher risk of death.

The process usually starts with a detailed history and examination. Your doctor will ask about breathlessness, cough, exposures at work or home, and any joint or skin symptoms that might suggest connective tissue disease. A chest X-ray may be done first, but its sensitivity for subtle changes is low. The radiographic standard is a high-resolution CT (HRCT) of the chest. An experienced radiologist should interpret the images.

HRCT patterns are categorised as:

• UIP
• Probable UIP
• Indeterminate
• Alternative diagnosis

A UIP pattern shows subpleural, basilar reticular opacities with honeycombing and traction bronchiectasis. If the HRCT shows a clear UIP pattern in the right clinical setting (typically a man over 60 with a smoking history and no features of connective tissue disease or hypersensitivity pneumonitis), a multidisciplinary discussion (MDT) can confirm IPF without a biopsy.

For probable UIP, indeterminate, or alternative patterns, further tests such as bronchoalveolar lavage (BAL) or surgical lung biopsy may be recommended after MDT review. Transbronchial lung cryobiopsy is an acceptable alternative to surgical biopsy in centres with expertise. Blood tests are not useful to diagnose IPF but are done to exclude connective tissue disease.

Serum biomarkers are not recommended for the sole purpose of distinguishing IPF from other ILDs. Pulmonary function tests (PFTs), including spirometry and diffusion capacity (DLCO), are integral for staging severity and monitoring progression. A six-minute walk test checks oxygen levels with exertion.

Non-Surgical Treatment Options for Interstitial Lung Disease and When Surgery Is Advised

There were no disease-specific treatments for ILD until antifibrotic therapy was introduced. Two antifibrotic medicines are used: nintedanib and pirfenidone. Nintedanib blocks several tyrosine kinases involved in scarring. In two large phase 3 trials (INPULSIS-1 and INPULSIS-2), nintedanib reduced the annual rate of decline in forced vital capacity (FVC) by about half compared to placebo.

The adjusted annual decline was -114.7 ml with nintedanib versus -239.9 ml with placebo, a difference of 125.3 ml. A relative reduction of about 48% was seen in the proportion of patients who had a large FVC drop or died. Diarrhoea is the most common side effect and led to stopping the medicine in less than 5% of patients.

Pirfenidone also slows disease progression. In two of three phase 3 trials, it reduced the decline in FVC or vital capacity. In the third trial, the primary endpoint was not met. A higher proportion of patients had no decline in FVC on pirfenidone compared to placebo. Both medicines need regular blood tests to check liver function.

Antifibrotics are indicated for:

• IPF
• Systemic sclerosis associated ILD
• Progressive pulmonary fibrosis (PPF)

Nintedanib has a conditional recommendation for PPF. Guidelines recommend starting antifibrotic therapy promptly at diagnosis, as IPF is irreversibly progressive from that point. A combination of prednisone, azathioprine, and N-acetylcysteine was once widely used but is now known to increase the risk of death and hospitalisation. Antacid medicines and anti-reflux surgery are not recommended for the purpose of improving IPF outcomes.

Pulmonary rehabilitation improves exercise capacity, breathlessness, and quality of life in the short term. Starting early after diagnosis gives the most benefit. Oxygen therapy is assessed with a six-minute walk test; if saturation drops below 88%, oxygen titration is done. Vaccinations against influenza, pneumococcus, and COVID-19 are advised. Acute exacerbations may need hospital admission, high-flow oxygen, ventilator support, antibiotics, and corticosteroids.

Surgery in the form of video-assisted thoracoscopic surgery (VATS) biopsy is advised only when HRCT and MDT cannot give a confident diagnosis, usually for indeterminate patterns. For a clear UIP pattern on HRCT, guidelines strongly recommend against surgical biopsy. VATS biopsy requires general anaesthesia and a hospital stay of 2 to 3 days.

Lung transplant evaluation is considered for patients with FVC below 80% predicted, DLCO below 40% predicted, significant FVC decline, oxygen desaturation below 88% on walk test, or honeycombing on HRCT. Early referral at diagnosis is recommended, not waiting for severe disease.

Your first visit and tests for Interstitial Lung Disease Care

When you come to Jaipur Hospital for interstitial lung disease care, your doctor will ask about your breathing difficulty, cough, and any exposure to dust, smoke or birds. They will listen for crackles at the base of your lungs and check for finger clubbing.

You should bring any previous chest X-rays, CT scans, pulmonary function test reports, and blood test results. A list of your current medicines and any known allergies helps the team plan safely.

The first visit usually includes a detailed clinical assessment and a review of your imaging. If you have not had a high-resolution CT (HRCT) of the chest, the doctor will order one. HRCT is the radiographic standard for diagnosing interstitial lung disease and shows patterns such as usual interstitial pneumonia (UIP), probable UIP, indeterminate, or an alternative diagnosis.

Pulmonary function tests (spirometry, lung volumes, and diffusion capacity) are also done to measure how much air your lungs hold and how well oxygen passes into your blood. Blood tests are usually requested to look for signs of connective tissue disease, which can cause lung fibrosis. In some cases, a six-minute walk test is used to check your oxygen level on exertion.

If the HRCT shows a clear UIP pattern in the right clinical setting — such as a man over 60 with a smoking history and no features of connective tissue disease or hypersensitivity pneumonitis — a multidisciplinary discussion (MDT) may confirm the diagnosis without a biopsy.

When the pattern is probable UIP, indeterminate, or suggests an alternative diagnosis, the MDT may recommend further tests such as bronchoscopy with lavage or a surgical lung biopsy. The MDT includes a pulmonologist, a radiologist experienced in ILD, and a pathologist who review all findings together. This discussion typically takes 45 to 60 minutes.

How treatment works for Interstitial Lung Disease Care

Treatment depends on the specific type of interstitial lung disease identified after the multidisciplinary discussion. For idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), antifibrotic medicines are the mainstay. The two antifibrotics used are nintedanib and pirfenidone. Nintedanib is an intracellular inhibitor that targets multiple tyrosine kinases involved in fibrosis pathways. Pirfenidone works through anti-fibrotic and anti-inflammatory mechanisms.

Both medicines slow the decline in forced vital capacity (FVC), which reflects a slowing of disease progression. Your doctor will choose the medicine based on your liver function, other medical conditions, and the side-effect profile.

Antifibrotic therapy is usually started promptly after diagnosis because IPF is irreversibly progressive from the moment of diagnosis. You will need regular blood tests to monitor liver enzymes, typically every two weeks for the first month, then monthly for three months, and then every three months.

Nintedanib commonly causes diarrhoea, which occurs in about 1 in 10 people and leads to stopping the medicine in less than 5% of patients in studies.

Pirfenidone can cause:

• Nausea
• Rash
• Sensitivity to sunlight

Your doctor will advise on dose adjustments or supportive medicines to manage these effects.

Pulmonary rehabilitation is recommended early after diagnosis and is associated with short-term improvements in exercise capacity, breathlessness, and quality of life. The programme includes supervised exercise training, breathing techniques, and education. If your oxygen level drops below 88% during a six-minute walk test, supplemental oxygen may be prescribed.

For acute exacerbations — a sudden worsening of breathlessness — hospital admission may be needed for oxygen, antibiotics, and corticosteroids. In advanced disease, lung transplantation is considered; referral is advised at the time of diagnosis for eligible patients so that evaluation and waitlisting can begin early.

If the HRCT and MDT cannot reach a confident diagnosis, a surgical lung biopsy by video-assisted thoracoscopic surgery (VATS) may be recommended. This is a referral to a thoracic surgeon and involves a 2 to 3 day hospital stay under general anaesthesia. Transbronchial lung cryobiopsy is an alternative in centres with appropriate expertise. The biopsy helps distinguish UIP from other patterns such as nonspecific interstitial pneumonia (NSIP) or hypersensitivity pneumonitis.

Risks and possible complications of Interstitial Lung Disease Care

The main risks come from the disease itself and from the medicines used to treat it. Acute exacerbation is a life-threatening complication where breathlessness worsens rapidly over days to weeks, often requiring hospitalisation. Patients with progressive disease are more prone to these episodes.

In studies, the combination of prednisone, azathioprine, and N-acetylcysteine — once used for IPF — was associated with an increased rate of death and hospitalisation compared to placebo. This combination is no longer recommended.

Nintedanib commonly causes diarrhoea; in clinical trials it led to discontinuation in less than 5% of patients. Liver enzyme elevations can occur with both nintedanib and pirfenidone, which is why regular blood monitoring is required. Pirfenidone may cause photosensitivity (sun sensitivity), rash, and nausea.

Antacid medicines (proton pump inhibitors or H2 blockers) are not recommended for the purpose of improving IPF respiratory outcomes, as guidelines found no evidence of respiratory benefit. Antireflux surgery is also not recommended for improving IPF outcomes.

If a surgical lung biopsy (VATS) is needed, the risks include air leak from the lung, bleeding, infection, and pain at the incision sites. General anaesthesia carries its own small risks, which the anaesthetist will discuss with you. The hospital stay for VATS biopsy is typically 2 to 3 days. Complications from cryobiopsy include bleeding and pneumothorax (collapsed lung), which may require a chest drain.

Recovery and aftercare for Interstitial Lung Disease Care

Interstitial lung disease is a chronic condition that requires long-term management. There is no heal, but antifibrotic treatment slows the decline in lung function. After starting antifibrotics, you will have follow-up visits every 4 to 12 weeks initially, then every 3 to 6 months once stable. Each follow-up takes about 30 minutes.

At these visits, your doctor reviews symptoms, checks your weight, reviews blood tests for liver function, and may repeat pulmonary function tests every 3 to 6 months to track FVC trends.

You should call the hospital or attend the emergency department if you develop a sudden increase in breathlessness, new or worsening cough with fever, coughing up blood, or if you cannot manage diarrhoea or nausea from the medicines. Acute exacerbations need urgent assessment.

Keep a record of your oxygen saturation if you use a pulse oximeter at home, and tell your doctor if it drops below 88% on exertion.

Pulmonary rehabilitation sessions are usually held 2 to 3 times a week for 6 to 8 weeks. Continuing the exercises at home helps maintain the benefits. If you are on oxygen, use it as prescribed during activity and sleep. Vaccinations — annual influenza, pneumococcal, and COVID-19 boosters — are important to reduce the risk of respiratory infections.

Manage other conditions such as hypertension, diabetes, and coronary artery disease with your treating doctors, as these comorbidities are common in ILD and affect outcomes.

Results of Interstitial Lung Disease Care

In studies, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) by about half compared to placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo, a difference of 125.3 ml (95% confidence interval 77.7 to 172.8 ml).

There was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of predicted FVC or who died. The proportion of patients with no decline in FVC was significantly higher with pirfenidone compared to placebo in two of three phase 3 trials. In the third trial, the primary endpoint was not met.

Antifibrotic therapy is associated with reduced mortality in IPF across pooled trial data. However, these results come from groups of patients in clinical trials; individual responses vary. Progressive pulmonary fibrosis (PPF) is defined by worsening symptoms, physiological progression (FVC decline ≥5% or DLCO decline ≥10%), or radiological progression on HRCT within one year. Patients with PPF may also benefit from antifibrotic therapy; nintedanib has a conditional recommendation for PPF.

Pulmonary rehabilitation shows short-term improvements in exercise tolerance, dyspnoea, and quality of life in ILD including IPF. Early referral for lung transplant evaluation allows time for assessment and waitlisting; criteria include FVC <80% predicted, DLCO <40% predicted, significant FVC decline, oxygen desaturation below 88% on six-minute walk test, or honeycombing on HRCT.

Delays in diagnosis of one to three years are common and are associated with increased risk of death, which underscores the importance of early specialist referral.

Cost and insurance for Interstitial Lung Disease Care in Jaipur

At Jaipur Hospital, a consultation for interstitial lung disease typically costs ₹2,000 to ₹6,000. The HRCT chest plus pulmonary function test package is usually ₹15,000 to ₹30,000. Antifibrotic medicines (nintedanib or pirfenidone) cost approximately ₹50,000 to ₹1,50,000 per month, depending on the drug and dose.

If a surgical lung biopsy (VATS) is needed, the typical range in India is ₹1,50,000 to ₹3,00,000; ask us for an estimate based on your case. These are typical ranges; the final cost depends on the investigations required, the choice of antifibrotic, duration of treatment, and whether hospital admission is needed for exacerbations or biopsy.

Jaipur Hospital is empanelled under RGHS, MAA Yojana, and CGHS, and works with a panel of private insurers and third-party administrators (TPAs). Coverage for consultations, investigations, and medicines depends on your specific policy and scheme rules. Pre-authorisation may be required for antifibrotic drugs and for surgical procedures.

The hospital's insurance desk can help you understand your benefits and submit the necessary documents. Bring your scheme card or insurance policy details at the time of registration. The hospital has an in-house pharmacy and diagnostic laboratory, so tests and medicines can be obtained on-site.